Literature DB >> 7889225

The AB/BA crossover: past, present and future?

S Senn1.   

Abstract

The AB/BA design is reviewed from a historical perspective. Particular attention is paid to the problem of carry-over and various attempts to deal with it. The two-stage procedure, an approach which was popular for many years, is shown to be unsafe. The analysis of AB/BA designs with baseline data is also considered. It is shown that such baselines do not provide a cure for the problem of carry-over; and it is concluded that any rational analysis of such trials will always be dependent on assumptions regarding carry-over, and that it is necessary to pay particular attention to washout periods. Under such circumstances analysis of covariance may be useful. In conclusion, some speculative comments about future lines of research are offered.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889225     DOI: 10.1177/096228029400300402

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  4 in total

1.  Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects.

Authors:  Andrew H Kemp; Tim Outhred; Sasha Saunders; Andre R Brunoni; Pradeep J Nathan; Gin S Malhi
Journal:  Psychopharmacology (Berl)       Date:  2013-12-15       Impact factor: 4.530

2.  Linear combinations come alive in crossover designs.

Authors:  Jonathan J Shuster
Journal:  Stat Med       Date:  2017-07-06       Impact factor: 2.373

3.  Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.

Authors:  Surya Panicker Rajeev; Victoria S Sprung; Carl Roberts; Jo A Harrold; Jason C G Halford; Andrej Stancak; Emma J Boyland; Graham J Kemp; Daniel J Cuthbertson; John P H Wilding
Journal:  BMJ Open       Date:  2017-01-27       Impact factor: 2.692

4.  The impact of escitalopram on vagally mediated cardiovascular function to stress and the moderating effects of vigorous physical activity: a randomized controlled treatment study in healthy participants.

Authors:  Camilla S Hanson; Tim Outhred; Andre R Brunoni; Gin S Malhi; Andrew H Kemp
Journal:  Front Physiol       Date:  2013-09-24       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.